Has Lara Troisi received payments from drug or device companies?

Yes. Drug and device makers reported $9,443 in general payments to Lara Troisi across 463 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lara Troisi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lara Troisi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lara Troisi

Psychiatric/Mental Health · Monticello, NYNPI 1528686185

Payments from drug & device makers

$9,443in general payments, 2019–2025

Across 463 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Teva Pharmaceuticals USA, Inc.$1K
Johnson & Johnson$1K
Otsuka America Pharmaceutical, Inc.$982
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$645
Axsome Therapeutics, Inc.$591
plus $2K from 18 others

What the payments were for

Food & beverage$9,26498%
Education$1792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	100	$2,059
Teva Pharmaceuticals USA, Inc.	70	$1,409
Johnson & Johnson	59	$1,351
Otsuka America Pharmaceutical, Inc.	50	$982
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	34	$645
Axsome Therapeutics, Inc.	31	$591
Alkermes, Inc.	27	$531
Neurocrine Biosciences, Inc.	17	$402
Supernus Pharmaceuticals, Inc.	13	$258
Braeburn Inc.	12	$248
Orexo US, Inc.	11	$208
Indivior Inc.	12	$203
Takeda Pharmaceuticals U.S.A., Inc.	5	$99
E.r. Squibb & Sons, L.L.C.	4	$82
Biogen	3	$78
Neuronetics, Inc.	1	$51
Vanda Pharmaceuticals Inc.	2	$50
Corium, LLC	5	$41
Tris Pharma Inc	2	$40
Pfizer	1	$30
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$29
Lundbeck LLC	1	$21
OWP Pharmaceuticals, Inc.	1	$20
Idorsia Pharmaceuticals US Inc	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,443 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AustedoDeutetrabenazine	25	$176,209
RexultiBrexpiprazole	39	$63,152
VraylarCariprazine Hcl	18	$28,272
AuvelityDextromethorphan Hbr/Bupropion	16	$19,560
Topiramate ErTopiramate	24	$13,951
TrintellixVortioxetine Hydrobromide	15	$7,054
Lurasidone Hcl	34	$5,780
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	29	$5,176
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	77	$2,612
Duloxetine Hcl	115	$2,309
Clonazepam	187	$1,965
Lamotrigine ErLamotrigine	12	$1,950
Atomoxetine Hcl	23	$1,762
Hydroxyzine Hcl	96	$1,752
Aripiprazole	92	$1,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo	$1,409	$176,20925 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$982	$63,15239 claims
AbbVieVraylar	$2,059	$28,27218 claims
Axsome Therapeutics, Inc.Auvelity	$591	$19,56016 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$99	$7,05415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Monticello

Glenn HannDansville$1.3M
Tammy RussoNiskayuna$568K
Carrie EdickSchenectady$484K
Eric SpronzCentereach$448K
Terry Jo Brooks-DevlinTonawanda$176K
Kevin SiewersStaten Island$155K
Daniel BreeyearNiskayuna$149K
Mary OlsonNew York$142K
Elijah StevensBinghamton$131K
Kayanna JonasFar Rockaway$93K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →